for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Genscript Biotech Corp

1548.HK

Latest Trade

15.92HKD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.60

 - 

21.70

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
15.92
Open
--
Volume
--
3M AVG Volume
181.62
Today's High
--
Today's Low
--
52 Week High
21.70
52 Week Low
10.60
Shares Out (MIL)
1,917.45
Market Cap (MIL)
30,218.98
Forward P/E
-27.92
Dividend (Yield %)
--

Next Event

Genscript Biotech Corp Annual Shareholders Meeting

Latest Developments

More

Genscript Biotech Says An Executive Director Agreed To Sell 15 Mln Shares Of Co

Genscript Biotech Says Wang Luquan To Sell 5 Mln Shares To Zhang Xiaolei At HK$17.32/Share

Genscript Biotech Updates On Separate Listing Of Legend Biotech Corp On Nasdaq Global Market

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Genscript Biotech Corp

Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.

Industry

Biotechnology & Drugs

Contact Info

No. 28

Yongxi Road, Jiangning Science Park

NANJING, JNG

China

+86.25.58897288

https://www.genscript.com

Executive Leadership

Fangliang Zhang

Executive Chairman of the Board, Chief Executive Officer

Ye Wang

President, Co-Founder, Executive Director

Yuan Xu

Chief Executive Officer of Legend

Xu Zhou

General Manager of Industrial Synthetic Biology Products of Bestzyme

Jiange Meng

Executive Director, Secretary of the Board

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.3K

2020(E)

0.3K
EPS (USD)

2017

0.015

2018

0.012

2019

-0.052

2020(E)

-0.090
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.26
Price To Book (MRQ)
9.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.30
LT Debt To Equity (MRQ)
1.40
Return on Investment (TTM)
-16.50
Return on Equity (TTM)
-13.01

Latest News

Latest News

BRIEF-Genscript Biotech Says An Executive Director Agreed To Sell 15 Mln Shares Of Co

* AN EXECUTIVE DIRECTOR AGREED TO SELL 15 MILLION SHARES OF CO

BRIEF-Genscript Biotech Says Wang Luquan To Sell 5 Mln Shares To Zhang Xiaolei At HK$17.32/Share

* WANG LUQUAN TO SELL THROUGH GS CORP TO ZHANG XIAOLEI 5 MILLION SHARES AT HK$17.32/SHARE

BRIEF-Genscript Biotech Updates On Separate Listing Of Legend Biotech Corp On Nasdaq Global Market

* UPDATES ON PROPOSED SPIN-OFF & SEPARATE LISTING OF LEGEND BIOTECH CORP ON NASDAQ GLOBAL MARKET

BRIEF-Genscript Files For Emergency Use Authorization Of Rapid Sars-Cov-2 Antibody Detection Kit

* GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

BRIEF-Genscript Biotech Says Legend Biotech Filed Registration Statement For IPO

* LEGEND BIOTECH FILED REGISTRATION STATEMENT FOR IPO OF 18.4 MILLION NEW ADSS IN PRICE RANGE BETWEEN US$18.00 AND US$20.00

BRIEF-Genscript Biotech Updates On Phase 1B/2 Cartitude-1 Study Evaluating JNJ-68284528

* UPDATES ON PHASE 1B/2 CARTITUDE-1 STUDY EVALUATING EFFICACY & SAFETY OF JNJ-68284528

BRIEF-Genscript Biotech Corp Says On 11 April, Rising Arrow Enterprise Entered Purchase Agreement

* GENSCRIPT BIOTECH CORP -ON 11 APRIL, RISING ARROW ENTERPRISE LTD ENTERED INTO PURCHASE AGREEMENT AS AN ADDITIONAL PARTY

BRIEF-Genscript Probio, Eutilex Enter Exclusive Strategic Collaboration For Car-T Programs

* GENSCRIPT PROBIO AND EUTILEX ENTER INTO EXCLUSIVE STRATEGIC COLLABORATION ON PLASMID AND VIRUS PROCESS DEVELOPMENT AND MANUFACTURING FOR CAR-T PROGRAMS Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Says Unit Sells 19.3 Million Series A Preference Shares For US$150.5 Mln

* UNIT SELLS 19.3 MILLION SERIES A PREFERENCE SHARES FOR US$150.5 MILLION TO JOHNSON & JOHNSON INNOVATION, LAV BIOSCIENCES FUND & OTHERS Source text for Eikon: Further company coverage:

BRIEF-Genscript Biotech Corp Posts Loss For Year Us$117.5 Million

* LOSS FOR YEAR US$117.5 MILLION VERSUS PROFIT OF US$20.8 MILLION

BRIEF-Genscript Biotech Submits Proposal To Stock Exchange For Spin-Off Of Cell Therapy Business

* SUBMITTED PROPOSAL TO STOCK EXCHANGE IN RELATION TO PROPOSED SPIN-OFF OF CELL THERAPY BUSINESS OPERATED BY UNIT

BRIEF-Genscript Biotech Corp Expect Loss Of About Us$114.0 Million To Us$144.0 Million For Year

* EXPECT LOSS OF ABOUT US$114.0 MILLION TO US$144.0 MILLION FOR YEAR

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up